Sarepta Therapeutics Historical PE Ratio image   This SRPT PE ratio history page last updated 3/11/2024
Sarepta Therapeutics Historical PE Ratio Chart
PeriodPriceAdj. EPSAnnualizedPE
Q4 2023
2/28/2024
137.500.823.2841.9
Q3 2023
11/1/2023
76.520.371.4851.7
Q2 2023
8/2/2023
105.19-0.85-3.40NA
Q1 2023
5/2/2023
123.69-0.97-3.88NA
Q4 2022
2/28/2023
122.13-0.53-2.12NA
Q3 2022
11/2/2022
113.42-0.80-3.20NA
Q2 2022
8/2/2022
94.01-1.18-4.72NA
Q1 2022
5/4/2022
72.75-0.56-2.24NA
Q4 2021
3/1/2022
76.02-0.77-3.08NA
Q3 2021
11/3/2021
86.53-0.19-0.76NA
Q2 2021
8/4/2021
67.50-1.52-6.08NA
Q1 2021
5/5/2021
72.77-1.54-6.16NA
Q4 2020
3/1/2021
87.03-1.84-7.36NA
Q3 2020
11/5/2020
145.15-1.42-5.68NA
Q2 2020
8/5/2020
158.89-1.51-6.04NA
Q1 2020
5/6/2020
122.57-1.04-4.16NA
Q4 2019
2/26/2020
113.63-1.57-6.28NA
Q3 2019
11/7/2019
93.38-1.14-4.56NA
Q2 2019
8/7/2019
142.26-0.83-3.32NA
Q1 2019
5/8/2019
114.50-0.75-3.00NA
Q4 2018
2/27/2019
151.68-0.85-3.40NA
Q3 2018
10/24/2018
123.04-0.56-2.24NA
Q2 2018
8/8/2018
121.02-0.43-1.72NA
Q1 2018
5/3/2018
78.17-0.28-1.12NA
Q4 2017
3/1/2018
62.11-0.28-1.12NA
Q3 2017
10/25/2017
48.36-0.20-0.80NA
Q2 2017
7/19/2017
34.08-0.46-1.84NA
Q1 2017
4/27/2017
34.72-0.60-2.40NA
Q4 2016
2/28/2017
31.11-0.71-2.84NA
Q3 2016
10/27/2016
40.81-0.95-3.80NA
Q2 2016
7/19/2016
21.14-1.19-4.76NA
Q1 2016
5/5/2016
16.76-1.15-4.60NA
Q4 2015
2/25/2016
14.36-1.30-5.20NA
Q3 2015
11/5/2015
24.28-1.11-4.44NA
Q2 2015
8/6/2015
34.63-0.87-3.48NA
Q1 2015
5/7/2015
15.04-1.15-4.60NA
Q4 2014
2/26/2015
13.82-0.94-3.76NA
Q3 2014
11/6/2014
16.26-0.70-2.80NA
Q2 2014
8/7/2014
19.90-0.61-2.44NA
Q1 2014
5/8/2014
31.10-0.55-2.20NA
Q4 2013
2/27/2014
29.86-0.77-3.08NA
Q3 2013
11/12/2013
13.16-0.63-2.52NA
Q2 2013
8/8/2013
36.85-0.46-1.84NA
Q1 2013
5/9/2013
33.08-0.41-1.64NA
Q4 2012
3/7/2013
30.21-2.36-9.44NA
Q3 2012
11/7/2012
22.61-2.17-8.68NA
Q2 2012
8/7/2012
8.310.361.445.8
Sarepta Therapeutics PE History Chart
PeriodPriceAdj. EPSTTMPE
Q4 2023
2/28/2024
137.500.82-0.63NA
Q3 2023
11/1/2023
76.520.37-1.98NA
Q2 2023
8/2/2023
105.19-0.85-3.15NA
Q1 2023
5/2/2023
123.69-0.97-3.48NA
Q4 2022
2/28/2023
122.13-0.53-3.07NA
Q3 2022
11/2/2022
113.42-0.80-3.31NA
Q2 2022
8/2/2022
94.01-1.18-2.70NA
Q1 2022
5/4/2022
72.75-0.56-3.04NA
Q4 2021
3/1/2022
76.02-0.77-4.02NA
Q3 2021
11/3/2021
86.53-0.19-5.09NA
Q2 2021
8/4/2021
67.50-1.52-6.32NA
Q1 2021
5/5/2021
72.77-1.54-6.31NA
Q4 2020
3/1/2021
87.03-1.84-5.81NA
Q3 2020
11/5/2020
145.15-1.42-5.54NA
Q2 2020
8/5/2020
158.89-1.51-5.26NA
Q1 2020
5/6/2020
122.57-1.04-4.58NA
Q4 2019
2/26/2020
113.63-1.57-4.29NA
Q3 2019
11/7/2019
93.38-1.14-3.57NA
Q2 2019
8/7/2019
142.26-0.83-2.99NA
Q1 2019
5/8/2019
114.50-0.75-2.59NA
Q4 2018
2/27/2019
151.68-0.85-2.12NA
Q3 2018
10/24/2018
123.04-0.56-1.55NA
Q2 2018
8/8/2018
121.02-0.43-1.19NA
Q1 2018
5/3/2018
78.17-0.28-1.22NA
Q4 2017
3/1/2018
62.11-0.28-1.54NA
Q3 2017
10/25/2017
48.36-0.20-1.97NA
Q2 2017
7/19/2017
34.08-0.46-2.72NA
Q1 2017
4/27/2017
34.72-0.60-3.45NA
Q4 2016
2/28/2017
31.11-0.71-4.00NA
Q3 2016
10/27/2016
40.81-0.95-4.59NA
Q2 2016
7/19/2016
21.14-1.19-4.75NA
Q1 2016
5/5/2016
16.76-1.15-4.43NA
Q4 2015
2/25/2016
14.36-1.30-4.43NA
Q3 2015
11/5/2015
24.28-1.11-4.07NA
Q2 2015
8/6/2015
34.63-0.87-3.66NA
Q1 2015
5/7/2015
15.04-1.15-3.40NA
Q4 2014
2/26/2015
13.82-0.94-2.80NA
Q3 2014
11/6/2014
16.26-0.70-2.63NA
Q2 2014
8/7/2014
19.90-0.61-2.56NA
Q1 2014
5/8/2014
31.10-0.55-2.41NA
Q4 2013
2/27/2014
29.86-0.77-2.27NA
Q3 2013
11/12/2013
13.16-0.63-3.86NA
Q2 2013
8/8/2013
36.85-0.46-5.40NA
Q1 2013
5/9/2013
33.08-0.41-4.58NA
Q4 2012
3/7/2013
30.21-2.36NANA
Q3 2012
11/7/2012
22.61-2.17NANA
Q2 2012
8/7/2012
8.310.36NANA
Quotes delayed 20 minutes

Email EnvelopeFree SRPT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Sarepta Therapeutics (SRPT) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

SRRA PE Ratio History
SRRK PE Ratio History
SRTS PE Ratio History
SSKN PE Ratio History
STAA PE Ratio History
STAB PE Ratio History
STE PE Ratio History
STIM PE Ratio History
STOK PE Ratio History
STRO PE Ratio History
How should the SRPT historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Sarepta Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this SRPT Historical PE Ratio page.

What is the average historical PE for SRPT based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The SRPT historical PE ratio using the annualized quarterly earnings method works out to 33.1.

What is the average historical PE for SRPT based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The SRPT historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Sarepta Therapeutics Historical PE Ratio information for Sarepta Therapeutics' stock. The average SRPT historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 33.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average SRPT historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this SRPT historical PE result, against the recent PE: when this page was posted on 3/8/2024, the most recent closing price for SRPT had been 124.37, and the most recent quarterly earnings result, annualized, was 3.28. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent SRPT PE on 3/8/2024 based on annualized quarterly EPS was 37.9. Based on SRPT's history, that recent PE is elevated relative to the historical average, with the recent PE 14.5% higher than the historical average PE across our data set for Sarepta Therapeutics.

For self directed investors doing their due diligence on SRPT or any other given stock, valuation analysis for SRPT can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Sarepta Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SRPT. Thanks for visiting, and the next time you need to research SRPT Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Institutional Holders of GMUN, TAP Historical Stock Prices, Institutional Holders of PGN.

 

Sarepta Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.